CareDx (1K9) Stock Overview
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1K9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
CareDx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.10 |
| 52 Week High | US$18.03 |
| 52 Week Low | US$9.83 |
| Beta | 2.54 |
| 1 Month Change | -2.83% |
| 3 Month Change | -3.66% |
| 1 Year Change | -13.26% |
| 3 Year Change | 70.91% |
| 5 Year Change | -77.80% |
| Change since IPO | 107.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1K9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -1.7% | 2.6% |
| 1Y | -13.3% | 3.3% | 11.4% |
Return vs Industry: 1K9 underperformed the German Biotechs industry which returned 3.3% over the past year.
Return vs Market: 1K9 underperformed the German Market which returned 11.4% over the past year.
Price Volatility
| 1K9 volatility | |
|---|---|
| 1K9 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 1K9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1K9's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes.
CareDx, Inc. Fundamentals Summary
| 1K9 fundamental statistics | |
|---|---|
| Market cap | €728.80m |
| Earnings (TTM) | -€18.21m |
| Revenue (TTM) | €323.82m |
Is 1K9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1K9 income statement (TTM) | |
|---|---|
| Revenue | US$379.81m |
| Cost of Revenue | US$123.24m |
| Gross Profit | US$256.57m |
| Other Expenses | US$277.92m |
| Earnings | -US$21.35m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 67.55% |
| Net Profit Margin | -5.62% |
| Debt/Equity Ratio | 0% |
How did 1K9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 00:22 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CareDx, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |